240 related articles for article (PubMed ID: 23728850)
1. The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis.
Cui Y; Zong H; Yang C; Yan H; Zhang Y
Int Urol Nephrol; 2013 Aug; 45(4):979-87. PubMed ID: 23728850
[TBL] [Abstract][Full Text] [Related]
2. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
[TBL] [Abstract][Full Text] [Related]
3. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Zhang Y
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):132-43. PubMed ID: 24445948
[TBL] [Abstract][Full Text] [Related]
4. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
Lin VC; Liao CH; Wang CC; Kuo HC
J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231
[TBL] [Abstract][Full Text] [Related]
5. The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis.
Cui Y; Zhang Y
Eur Urol; 2013 Nov; 64(5):811-22. PubMed ID: 23567065
[TBL] [Abstract][Full Text] [Related]
6. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia.
Kang D; Hu C; Fu Y; Wang D
Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
[TBL] [Abstract][Full Text] [Related]
8. An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate.
Xu Z; Chen X; Zhou H; Ren C; Wang Q; Pan Y; Liu L; Liu X
Front Endocrinol (Lausanne); 2024; 15():1335146. PubMed ID: 38344665
[TBL] [Abstract][Full Text] [Related]
9. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.
Kacker R; Harisaran V; Given L; Miner M; Rittmaster R; Morgentaler A
Andrologia; 2015 Mar; 47(2):148-52. PubMed ID: 24499051
[TBL] [Abstract][Full Text] [Related]
10. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.
Bhasin S; Travison TG; Storer TW; Lakshman K; Kaushik M; Mazer NA; Ngyuen AH; Davda MN; Jara H; Aakil A; Anderson S; Knapp PE; Hanka S; Mohammed N; Daou P; Miciek R; Ulloor J; Zhang A; Brooks B; Orwoll K; Hede-Brierley L; Eder R; Elmi A; Bhasin G; Collins L; Singh R; Basaria S
JAMA; 2012 Mar; 307(9):931-9. PubMed ID: 22396515
[TBL] [Abstract][Full Text] [Related]
11. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
12. Effects of androgen deficiency and replacement on prostate zonal volumes.
Jin B; Conway AJ; Handelsman DJ
Clin Endocrinol (Oxf); 2001 Apr; 54(4):437-45. PubMed ID: 11318778
[TBL] [Abstract][Full Text] [Related]
13. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis.
Kohn TP; Mata DA; Ramasamy R; Lipshultz LI
Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809
[TBL] [Abstract][Full Text] [Related]
14. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
15. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
17. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis.
Kang DY; Li HJ
Medicine (Baltimore); 2015 Jan; 94(3):e410. PubMed ID: 25621688
[TBL] [Abstract][Full Text] [Related]
18. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Helfand BT; Blackwell RH; McVary KT
J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
[TBL] [Abstract][Full Text] [Related]
19. Benign prostatic hyperplasia progression and its impact on treatment.
Djavan B; Waldert M; Ghawidel C; Marberger M
Curr Opin Urol; 2004 Jan; 14(1):45-50. PubMed ID: 15091050
[TBL] [Abstract][Full Text] [Related]
20. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.
Liu L; Zhao S; Li F; Li E; Kang R; Luo L; Luo J; Wan S; Zhao Z
J Sex Med; 2016 Sep; 13(9):1297-1310. PubMed ID: 27475241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
